Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website https://jmc.elmerpub.com

Case Report

Volume 17, Number 4, April 2026, pages 146-152

High-Risk Chronic Lymphocytic Leukemia in a Young Adult Treated With Reduced-Dosage, Fixed-Duration Ibrutinib and Venetoclax

Figures

Figure 1.
Figure 1. (a) Mature lymphocytes (red arrows), and prolymphocyte (yellow arrow). (b) Basket cell/smudge cell (black arrow).
Figure 2.
Figure 2. (a) Hypercellular bone marrow partially effaced by a population of atypical round cells that comprise approximately 80–90% of the marrow cellularity (arrows). The atypical cells show strong membranous staining for CD20 (b), moderate-to-strong membranous staining for CD5 (c) and are negative for cyclin-D1 (d). Taken together, the immuno-morphologic features support involvement by chronic lymphocytic leukemia (arrows).
Figure 3.
Figure 3. Temporal evolution of hemoglobin and platelet counts in relation to blood transfusion and initiation of treatment with ibrutinib monotherapy, followed by ibrutinib and venetoclax combination. PRBC: packed red blood cell